Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLMD NASDAQ:GRI NASDAQ:HEPA NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLMDGalmed Pharmaceuticals$0.66+10.6%$0.62$0.41▼$2.34$3.26M0.62139,817 shs1.11 million shsGRIGRI Bio$2.15-4.9%$2.43$2.09▼$80.36$3.27M-1.2241,134 shs36,577 shsHEPAHepion Pharmaceuticals$0.10+5.7%$0.05$0.03▼$0.11$491K1.5219,503 shs97,921 shsVIVSVivoSim Labs$1.32+1.5%$1.59$1.25▼$5.30$3.39M1.4151,621 shs15,517 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLMDGalmed Pharmaceuticals+10.62%+5.11%-7.12%+7.42%-49.73%GRIGRI Bio-4.87%-4.44%-11.89%-6.93%-94.78%HEPAHepion Pharmaceuticals+15.15%+58.33%+97.92%+58.33%-21.81%VIVSVivoSim Labs+1.54%-6.38%-13.16%-34.00%+131,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLMDGalmed Pharmaceuticals$0.66+10.6%$0.62$0.41▼$2.34$3.26M0.62139,817 shs1.11 million shsGRIGRI Bio$2.15-4.9%$2.43$2.09▼$80.36$3.27M-1.2241,134 shs36,577 shsHEPAHepion Pharmaceuticals$0.10+5.7%$0.05$0.03▼$0.11$491K1.5219,503 shs97,921 shsVIVSVivoSim Labs$1.32+1.5%$1.59$1.25▼$5.30$3.39M1.4151,621 shs15,517 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLMDGalmed Pharmaceuticals+10.62%+5.11%-7.12%+7.42%-49.73%GRIGRI Bio-4.87%-4.44%-11.89%-6.93%-94.78%HEPAHepion Pharmaceuticals+15.15%+58.33%+97.92%+58.33%-21.81%VIVSVivoSim Labs+1.54%-6.38%-13.16%-34.00%+131,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLMDGalmed Pharmaceuticals 1.00SellN/AN/AGRIGRI Bio 2.33Hold$1,008.0046,783.72% UpsideHEPAHepion Pharmaceuticals 0.00N/AN/AN/AVIVSVivoSim Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest HEPA, VIVS, GRI, and GLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026GLMDGalmed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GRIGRI Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$2.88 per shareN/AGRIGRI BioN/AN/AN/AN/A$4.16 per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/AVIVSVivoSim Labs$140K24.61N/AN/A$5.54 per share0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLMDGalmed Pharmaceuticals-$10.31M-$1.24N/AN/AN/AN/A-29.43%-26.00%5/20/2026 (Estimated)GRIGRI Bio-$11.96M-$235.02N/AN/AN/AN/A-289.01%-171.12%5/21/2026 (Estimated)HEPAHepion Pharmaceuticals-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%N/AVIVSVivoSim Labs-$2.48M-$3.15N/AN/AN/A-861.27%-15.51%-11.31%N/ALatest HEPA, VIVS, GRI, and GLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GRIGRI Bio-$3.74N/AN/AN/AN/AN/A5/13/2026Q1 2026GRIGRI Bio-$3.74-$1.61+$2.13-$1.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AGRIGRI Bio$1.9188.84%N/AN/A N/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLMDGalmed PharmaceuticalsN/A6.556.55GRIGRI BioN/A3.253.25HEPAHepion PharmaceuticalsN/A1.301.30VIVSVivoSim LabsN/A2.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLMDGalmed Pharmaceuticals76.14%GRIGRI Bio33.95%HEPAHepion Pharmaceuticals17.24%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipGLMDGalmed Pharmaceuticals19.80%GRIGRI Bio8.73%HEPAHepion Pharmaceuticals0.06%VIVSVivoSim Labs2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLMDGalmed Pharmaceuticals205.48 million4.39 millionNot OptionableGRIGRI Bio11.45 million1.32 millionNot OptionableHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataVIVSVivoSim Labs202.61 million2.54 millionN/AHEPA, VIVS, GRI, and GLMD HeadlinesRecent News About These CompaniesVivoSim Labs IncMay 14 at 5:07 PM | cnn.comVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human ...April 30, 2026 | bakersfield.comBVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | financialpost.comFVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Real TimeApril 7, 2026 | nasdaq.comVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | financialpost.comFVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | globenewswire.comVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | financialpost.comFVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | globenewswire.comVivoSim Labs Stock Price HistoryMarch 4, 2026 | investing.comVivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 4, 2026 | finanznachrichten.deVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | financialpost.comFVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | globenewswire.comVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | financialpost.comFVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Analyst ResearchFebruary 4, 2026 | nasdaq.comWhy is VIVS stock up 79% today?January 30, 2026 | msn.comVivoSim Labs Expands Commercial Presence in Asia-Pacific with Distribution Agreements in Korea and China for NAMKind™ Toxicology ServicesJanuary 29, 2026 | quiverquant.comQVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaJanuary 29, 2026 | financialpost.comFVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaJanuary 29, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines1 Stock Is Powering the AI Boom and the Next Farm SupercycleBy Jeffrey Neal Johnson | April 22, 2026Chipotle Stock Just Hit Bottom—Is a Breakout Next?By Thomas Hughes | April 30, 2026The USMCA Review Is Coming: 3 Border-Sensitive Stocks to WatchBy Chris Markoch | May 8, 2026Astera Labs: The Tollbooth for AI's Traffic JamBy Jeffrey Neal Johnson | April 23, 20263 Agriculture Stocks to Buy as Food Inflation Stays Elevated in 2026By Chris Markoch | April 20, 2026HEPA, VIVS, GRI, and GLMD Company DescriptionsGalmed Pharmaceuticals NASDAQ:GLMD$0.66 +0.06 (+10.62%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.61 -0.05 (-7.06%) As of 07:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.GRI Bio NASDAQ:GRI$2.15 -0.11 (-4.87%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.24 +0.09 (+4.37%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Hepion Pharmaceuticals NASDAQ:HEPA$0.10 +0.01 (+5.67%) As of 05/14/2026 03:16 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.VivoSim Labs NASDAQ:VIVS$1.32 +0.02 (+1.54%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.38 +0.05 (+4.17%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
